Group 1 - Actuate Therapeutics, Inc. (ACTU) closed at $6.9, with a 4.9% gain over the past four weeks, and a mean price target of $21.67 suggests a 214.1% upside potential [1] - The average price target ranges from a low of $20.00 to a high of $25.00, with a standard deviation of $2.89, indicating a strong agreement among analysts [2] - Analysts show optimism regarding ACTU's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] Group 2 - The Zacks Consensus Estimate for ACTU has increased by 0.9% due to one upward revision in earnings estimates over the last 30 days [12] - ACTU holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Shares of OppFi Inc. (OPFI) have increased by 1.5% over the past four weeks, closing at $9.76, with a mean price target of $14.5 indicating a potential upside of 48.6% [1] - The mean estimate includes three short-term price targets with a standard deviation of $1.32, where the lowest estimate of $13.50 suggests a 38.3% increase, and the highest estimate of $16.00 indicates a 63.9% increase [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 10.6% over the last 30 days, with two estimates moving higher and no negative revisions [12] - OPFI holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Paysign, Inc. (PAYS) shows potential for significant upside, with a mean price target of $9.1 indicating a 74% increase from its current price of $5.23 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $0.65, suggesting a consensus among analysts [2] - The lowest estimate of $8.50 indicates a 62.5% increase, while the highest target of $10.00 suggests a 91.2% increase from the current price [2] - Analysts' price targets can be misleading, as they may not accurately reflect the stock's future price movements [3][7] Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding PAYS's ability to report better earnings, which supports the potential for stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 2.9%, with one estimate moving higher and no negative revisions [12] - PAYS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Rush Street Interactive, Inc. (RSI) shows potential for significant upside, with a mean price target of $23 indicating a 28.5% increase from its current price of $17.9 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.56, indicating variability among analysts [2] - The lowest estimate is $18.00, suggesting a 0.6% increase, while the highest estimate is $27.00, indicating a potential surge of 50.8% [2] - Analysts' price targets can be misleading, as they often set overly optimistic targets influenced by business relationships [7][8] Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding RSI's earnings prospects supports the expectation of an upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 23.9%, with two estimates moving higher and no negative revisions [12] - RSI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not reliably indicate the extent of potential gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Rapport Therapeutics, Inc. (RAPP) shares have increased by 9.5% in the last four weeks, closing at $29.43, with a potential upside of 75% based on Wall Street analysts' mean price target of $51.5 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $34.00 to a high of $80.00, with a standard deviation of $13.2, indicating variability among analysts [2] - The lowest estimate suggests a 15.5% increase from the current price, while the highest estimate indicates a potential upside of 171.8% [2] Analyst Sentiment - Analysts show a consensus that RAPP will report better earnings than previously estimated, which supports the expectation of a stock price increase [4][11] - The Zacks Consensus Estimate for the current year has risen by 7.4% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - RAPP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Price Movement Implications - While the consensus price target may not be a reliable indicator of the extent of RAPP's potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - LifeStance Health Group (LFST) has shown a significant price increase of 33.6% over the past four weeks, with a mean price target of $8.56 indicating a potential upside of 30.5% from its current price of $6.56 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1.1, suggesting variability in analyst predictions. The lowest estimate is $6.50 (0.9% decline), while the highest is $10.00 (52.4% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - There is increasing optimism among analysts about LFST's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for LFST's current year earnings has risen by 40%, with two estimates moving higher and no negative revisions [12] - LFST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in price predictions by analysts [3][7][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Core Viewpoint - Analyst recommendations play a significant role in influencing stock prices, but their reliability is questionable, particularly for On Holding (ONON) [1][5]. Group 1: Analyst Recommendations - On Holding has an average brokerage recommendation (ABR) of 1.48, indicating a consensus between Strong Buy and Buy, based on 24 brokerage firms [2]. - Out of the 24 recommendations, 17 are Strong Buy and 3 are Buy, which account for 70.8% and 12.5% of all recommendations respectively [2]. - Despite the positive ABR, relying solely on this information for investment decisions may not be advisable, as studies show brokerage recommendations often fail to guide investors effectively [5][11]. Group 2: Limitations of Brokerage Recommendations - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, leading to a disproportionate number of Strong Buy recommendations compared to Strong Sell [6][11]. - The ABR is calculated solely from brokerage recommendations, which may not reflect the actual potential for price appreciation [10][11]. - The Zacks Rank, which is based on earnings estimate revisions, is presented as a more reliable indicator of near-term stock performance compared to the ABR [8][12]. Group 3: Zacks Rank vs. ABR - The Zacks Rank is a quantitative model that utilizes earnings estimate revisions and is displayed in whole numbers, contrasting with the decimal-based ABR [9][10]. - The Zacks Rank is updated more frequently, reflecting timely changes in earnings estimates, while the ABR may not be current [13]. - On Holding has achieved a Zacks Rank 1 (Strong Buy) due to a 90.4% increase in the Zacks Consensus Estimate for the current year, indicating strong analyst optimism [14][15].

Core Viewpoint - Hinge Health Inc. (HNGE) has shown a 0.9% increase in stock price over the past four weeks, closing at $50.05, with analysts suggesting a potential upside of 29.6% based on a mean price target of $64.86 [1][11]. Price Targets - The average of 14 short-term price targets ranges from a low of $56.00 to a high of $72.00, with a standard deviation of $4.66, indicating a relatively high agreement among analysts [2][9]. - The lowest estimate suggests an 11.9% increase from the current price, while the highest estimate indicates a 43.9% upside [2]. Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with positive stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has increased by 4.6% over the past month, with seven estimates revised upward and no negative revisions [12]. Zacks Rank - HNGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13]. Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the exact price movement, it does provide a useful guide for potential price direction [14].

Core Viewpoint - Omnicell (OMCL) shares have increased by 24% in the past four weeks, closing at $36.66, with a potential upside of 30.9% based on Wall Street analysts' mean price target of $48 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $10.34, indicating variability among analysts; the lowest estimate suggests a 1.8% decline to $36.00, while the highest predicts a 71.9% increase to $63.00 [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about Omnicell's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, three earnings estimates for the current year have been revised upward, leading to a 17.5% increase in the Zacks Consensus Estimate [12] - Omnicell holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - One Stop Systems, Inc. (OSS) shares have increased by 16.4% recently, with analysts suggesting a potential upside of 42.9% based on a mean price target of $8.5 [1][4]. Price Targets - The average price target for OSS is $8.5, with estimates ranging from a low of $8.00 to a high of $9.00, indicating potential increases of 34.5% to 51.3% from the current price [2][4]. - The standard deviation of $0.5 suggests a relatively high agreement among analysts regarding the price targets [2][9]. Analyst Sentiment - Analysts have shown increasing optimism about OSS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 16.7%, with no negative revisions reported [12]. Zacks Rank - OSS holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Conclusion on Price Movement - While consensus price targets may not be entirely reliable, the direction indicated by these targets appears to be a useful guide for potential price movement [14].